Boston Scientific Stock Hits Key Support – Buying Opportunity?
Boston Scientific (BSX) stock should be on your watchlist. Here is why – it is currently trading in the support zone ($45.89 – $50.73), levels from which it has bounced meaningfully before. Since it first started trading, Boston Scientific stock received buying interest at this level 6 times and subsequently went on to generate 25.6% in average peak returns.
| Peak Return | Days to Peak Return | |
|---|---|---|
| 12/12/2022 | 0.1% | 1 |
| 1/12/2023 | 10.3% | 91 |
| 4/13/2023 | 4.4% | 33 |
| 5/30/2023 | 8.2% | 23 |
| 8/8/2023 | 8.1% | 21 |
| 10/12/2023 | 122.3% | 697 |
Yet, a support zone alone isn’t enough; rebounds are more likely when fundamentals, sentiment, and market conditions line up. How does that look for BSX?
Rebound likely; watch for Watchman stabilization.
Boston Scientific’s Q1 revenue and EPS beat estimates, supported by a $2 billion share repurchase. However, lowered 2026 guidance, citing slower WATCHMAN and electrophysiology segment growth, alongside tariff impacts on margins, pressures near-term outlook. Despite recent analyst price target reductions, a consensus ‘Moderate Buy’ persists, with the stock appearing undervalued. Positive industry trends like AI adoption offer tailwinds, but competitive headwinds are present. Insider buying suggests belief in long-term value at these support levels.
How Do BSX Financials Look Right Now?
- Revenue Growth: 17.4% LTM and 16.5% last 3-year average.
- Cash Generation: Nearly 16.0% free cash flow margin and 19.9% operating margin LTM.
- Recent Revenue Shocks: The minimum annual revenue growth in the last 3 years for BSX was 12.7%.
- Valuation: BSX stock trades at a PE multiple of 20.1
| BSX | S&P Median | |
|---|---|---|
| Sector | Health Care | – |
| Industry | Health Care Equipment | – |
| PE Ratio | 20.1 | 23.7 |
|
|
||
| LTM* Revenue Growth | 17.4% | 7.4% |
| 3Y Average Annual Revenue Growth | 16.5% | 5.7% |
| Min Annual Revenue Growth Last 3Y | 12.7% | 0.5% |
|
|
||
| LTM* Operating Margin | 19.9% | 18.4% |
| 3Y Average Operating Margin | 18.5% | 18.3% |
| LTM* Free Cash Flow Margin | 16.0% | 14.4% |
*LTM: Last Twelve Months | For more details on BSX fundamentals, read Buy or Sell BSX Stock.
And What If The Support Breaks?
BSX isn’t immune to big drops. It plunged 74% in the Dot-Com Bubble and 70% during the Global Financial Crisis. The Covid sell-off wiped out 43%, and even smaller shocks like 2018 and inflation saw dips of 19% and 25%. The stock has solid fundamentals, but sharp market downturns still hit hard. Risk remains real, no matter how sound the story looks.
But the risk is not limited to major market crashes. Stocks fall even when markets are in good shape – think events like earnings, business updates, outlook changes. Read BSX Dip Buyer Analyses to see how the stock has recovered from sharp dips in the past.
Still not sure about BSX stock? Consider the portfolio approach.
The Best Investors Think In Portfolios
Individual stocks can soar or tank, but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside, and mitigate the downside associated with any individual stock.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.